Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance

Clinical Respiratory Journal

Volumn 11, Issue 4, 2017, Pages 419-429

  Cao, Bin ^a,b   Qu, Jiu Xin ^a   Yin, Yu Dong ^a   Eldere, Johan Van ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

atypical; community acquired pneumonia; fluoroquinolones; macrolide resistant Mycoplasma pneumoniae; macrolides; resistance; tetracyclines

Indexed keywords

BACTERIAL RNA; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBOSOME RNA; TETRACYCLINE; QUINOLONE DERIVATIVE; RNA 23S; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL GENE; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; INAPPROPRIATE PRESCRIBING; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT FAILURE; COMMUNITY ACQUIRED INFECTION; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MEDICATION OVERUSE; MICROBIOLOGY;

COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MACROLIDES; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; POINT MUTATION; PRESCRIPTION DRUG OVERUSE; PREVALENCE; RESPIRATORY TRACT INFECTIONS; RNA, RIBOSOMAL, 23S; TETRACYCLINES;

EID: 85021708515     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12379     Document Type: Review

References (103)

1. File T, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122: 130–41.
2. Committee for The Japanese Respiratory Society Guidelines for the Management of Respiratory Infections. Guidelines for the management of community-acquired pneumonia in adults, revised edition. Respirology. 2006;11(Suppl. 3): S79–133.
3. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67: 71–9.
4. Welte T, Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ network. Semin Respir Critic Care Med. 2009;30: 127–35.
5. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl. 2): S27–72.
6. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect. 2011;17(Suppl. 6): E1–59.
7. Liu Y, Chen M, Zhao T, et al. Causative agent distribution and antibiotic therapy assessment among adult patients with community-acquired pneumonia in Chinese urban population. BMC Infect Dis. 2009;9: 31.
8. McIntosh K. Community-acquired pneumonia in children. N Engl J Med. 2002;346: 429–37.
9. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17: 697–728.
10. File TM, Jr. The science of selecting antimicrobials for community-acquired pneumonia (CAP). J Manage Care Pharm. 2009;15(Suppl.): S5–11.
11. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32: 956–73.
12. Odonkor ST, Addo KK. Bacteria resistance to antibiotics: recent trends and challenges. Int J Biol Med Res. 2011;2: 1204–10.
13. Zhao F, Lv M, Tao X, et al. Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China. Antimicrob Agents Chemother. 2012;56: 1108–9.
14. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010;16: 78–86.
15. Xin D, Mi Z, Han X, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother. 2009;53: 2158–9.
16. Cao B, Zhao C-J, Yin Y-D, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010;51: 189–94.
17. To KKW, Chan K-H, Fung Y-F, et al. Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia. Eur Resp J. 2010;36: 969–71.
18. Isozumi R, Yoshimine H, Morozumi M, et al. Adult community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae. Respirology. 2009;14: 1206–8.
19. Cardinale F, Chironna M, Dumke R, et al. Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J. 2011;37: 1522–4.
20. Park, D, Sherbin V, Goodman M, et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis. 2001;184: 268–77.
21. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J. 2002;20(Suppl. 36): 20s–7s.
22. von Baum H, Welte T, Marre R, et al. Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ). BMC Infect Dis. 2009;9: 62.
23. Song J-H, Thamlikitkul V, Hsueh P-R. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011;38: 108–17.
24. Tao L-L, Hu B-J, He L-X, et al. Etiology and antimicrobial resistance of community-acquired pneumonia in adult patients in China. Chin Med J. 2012;125: 2967–72.
25. Yin Y-D, Zhao F, Ren L-L, et al. Evaluation of the Japanese Respiratory Society guidelines for the identification of Mycoplasma pneumoniae pneumonia. Respirology. 2012;17: 1131–6.
26. Dey AB, Chaudhry R, Kumar P, et al. Mycoplasma pneumonia and community-acquired pneumonia. Natl Med J India. 2000;13: 66–70.
27. Miyashita N, Fukano H, Mouri K, et al. Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study. J Med Microbiol. 2005;54: 395–400.
28. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113: 701–7.
29. Principi N, Esposito S, Blasi F, et al.; Mowgli Study Group. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis. 2001;32: 1281–9.
30. Defilippi A, Silvestri M, Tacchella A, et al. Epidemiology and clinical features of Mycoplasma pneumoniae infection in children. Respir Med. 2008;102: 1762–8.
31. Chalker V, Stocki T, Litt D, et al. Increased detection of Mycoplasma pneumoniae infection in children in England and Wales, October 2011 to January 2012. Euro Surveill. 2012;17: Pii 20081.
32. Gadsby NJ, Reynolds AJ, McMenamin J, et al. Increased reports of Mycoplasma pneumoniae from laboratories in Scotland in 2010 and 2011 – impact of the epidemic in infants. Euro Surveill. 2012;17: Pii: 20110.
33. Zhang Q, Guo Z, MacDonald NE. Vaccine preventable community-acquired pneumonia in hospitalized children in Northwest China. Pediatr Infect Dis J. 2011;30: 7–10.
34. Samransamruajkit R, Jitchaiwat S, Wachirapaes W, et al. Prevalence of Mycoplasma and Chlamydia pneumonia in severe community-acquired pneumonia among hospitalized children in Thailand. Jpn J Infect Dis. 2008;61: 36–9.
35. Chen CJ, Lin PY, Tsai MH, et al. Etiology of community-acquired pneumonia in hospitalized children in northern Taiwan. Pediatr Infect Dis J. 2012;31: e196–201.
36. Nakayama E, Hasegawa K, Morozumi M, et al. Rapid optimization of antimicrobial chemotherapy given to paediatric patients with community-acquired pneumonia using PCR techniques with serology and standard culture. J Infect Chemother. 2007;13: 305–13.
37. Jacobs E. Mycoplasma pneumoniae: now in the focus of clinicians and epidemiologists. Euro Surveill. 2012;17: Pii: 20084.
38. Lenglet A, Herrador Z, Magiorakos AP, et al. European Working Group on Mycoplasma pneumoniae surveillance. Surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area, January 2012. Euro Surveill. 2012;17: Pii 20075.
39. Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol. 2011;6: 423–31.
40. Matsuoka M, Narita M, Okazaki N, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother. 2004;48: 4624–30.
41. Kawai Y, Miyashita N, Kubo M, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother. 2013;57(8): 4046–49.
42. Akaike H, Miyashita N, Kubo M, et al. In vitro activities of 11 antimicrobial agents against macrolide-resistant Mycoplasma pneumoniae isolates from paediatric patients: results from a multicenter surveillance study. Jpn J Infect Dis. 2012;65: 535–8.
43. Zhou Z, Li X, Chen X, et al. Macrolide-resistant mycoplasma pneumoniae in adults in Zhejiang, China. Antimicrob Agents Chemother. 2015;59: 1048–51.
44. Pereyre S, Touati A, Petitjean-Lecherbonnier J, et al. The increased incidence of Mycoplasma pneumoniae in France in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains. Clin Microbiol Infect. 2013;19: E212–7.
45. Peuchant O, Menard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009;64: 52–8.
46. Dumke R, Lück C, Jacobs E. Low rate of macrolide resistance in Mycoplasma pneumoniae strains in Germany between 2009 and 2012. Antimicrob Agents Chemother. 2013;57: 3460.
47. Dumke R, von Baum H, Lück PC, Jacobs E. Occurrence of macrolide resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect. 2009;16: 613–6.
48. Yamada M, Buller R, Bledsoe S, et al. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis. 2012;31: 409–11.
49. Uldum SA, Bangsborg JM, Gahrn-Hansen B, et al. Epidemic of Mycoplasma pneumoniae infection in Denmark, 2010 and 2011. Euro Surveill. 2012;17(5): 20073.
50. Eshaghi A, Memari N, Tang P, et al. Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010-2011. Emerg Infect Dis. 2013;19: 1525–7.
51. Chironna M, Sallustio A, Esposito S, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother. 2011;66: 734–7.
52. Pereyre S, Charron A, Hidalgo-Grass C, et al. The spread of Mycoplasma pneumoniae is polyclonal in both an endemic setting in France and in an epidemic setting in Israel. PLoS One. 2012;7: e38585.
53. Saegeman V, Proesmans M, Dumke R. Management of macrolide-resistant Mycoplasma pneumoniae infection. Pediatr Infect Dis J. 2012;31: 1210–1.
54. Caballero J, del Campo R, del Carmen Mafé M, et al. First report of macrolide resistance in a Mycoplasma pneumoniae isolate causing community-acquired pneumonia in Spain. Antimicrob Agents Chemother. 2014;58: 1265–66.
55. Averbuch D, Hidalgo-Grass C, Moses AE, et al. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis. 2011;17: 1079–82.
56. Pereyre S, Guyot C, Renaudin H, et al. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2004;48: 460–5.
57. Van de Sande-Bruinsma N, Grundmann H, Verloo D, et al; European Antimicrobial Resistance Surveillance System Group; European Surveillance of Antimicrobial Consumption Project Group. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis. 2008;14: 1722–30.
58. Hinnerskov M, Therkildsen JM, Cordoba G, et al. Macrolide overuse for treatment of respitatory tract infections in general practice. Dan Med Bull. 2011;58: A4356.
59. Kotwani A, Holloway K. Antibiotic prescribing practice for acute, uncomplicated respiratory tract infections in primary care settings in New Dehli, India. Trop Med Int Health. 2014;19: 761–8.
60. Biswas M, Roy DN, Tajmim A, et al. Prescription antibiotics for outpatients in Bangladesh: a cross-sectional health survey conducted in three cities. Ann Clin Microbiol Antimicrob. 2014;13: 15.
61. Li SL, Sun HM, Zhao HQ, et al. A single tube modified allele-specific-PCR for rapid detection of erythromycin-resistant Mycoplasma pneumoniae in Beijing. Chin Med J (Engl). 2012;125: 2671–6.
62. Ji M, Lee NS, Oh JM, et al. Single-nucleotide polymorphism PCR for the detection of Mycoplasma pneumoniae and determination of macrolide resistance in respiratory samples. J Microbiol Methods. 2014;102C: 32–6.
63. Liu Y, Ye X, Zhang H, et al. Rapid detection of Mycoplasma pneumoniae and its macrolide-resistance mutation by Cycleave PCR. Diagn Microbiol Infect Dis. 2014;78: 333–7.
64. Spuesens EB, Meijer A, Bierschenk D, et al. Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae in respiratory specimens collected between 1997 and 2008 in The Netherlands. J Clin Microbiol. 2012;50: 1999–2004.
65. Wolff BJ, Thacker L, Schwartz S, Winchell J. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agent Chemother. 2008;52: 3542–9.
66. Yin Y-D, Cao B, Wang H, et al. Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing, China. Chin J Tuberc Respir Dis. 2013;36: 1–5.
67. Xue G, Wang Q, Yan C, et al. Molecular characterizations of PCR-positive Mycoplasma pneumoniae specimens collected from Australia and China. J Clin Microbiol. 2014;52: 1478–82.
68. Lin C, Li S, Sun H, et al. Nested PCR-linked capillary electrophoresis and single-strand conformation polymorphisms for detection of macrolide-resistant Mycoplasma pneumoniae in Beijing, China. J Clin Microbiol. 2010;48: 4567–72.
69. Liu Y, Ye X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009;53: 2160–2.
70. CLSI. Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline. CLSI Document M43-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2011
71. Wierzbowski AK, Hoban DJ, Hisanaga T, et al. The use of macrolides in treatment of upper respiratory tract infections. Curr Allergy Asthma Rep 2006;6: 171–81.
72. Wang J, Wang P, Wang X, et al. Use and prescription of antibiotics in primary health care settings in China. JAMA Intern Med. 2014;174: 1914–20.
73. Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis. 2006;43: 432–8.
74. Bergman M, Huikko S, Huovinen P, et al; Finnish Study Group for Antimicrobial Resistance (FiRe Network). Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006;50: 3646–50.
75. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4. Ann Clin Microbiol Antimicrob. 2008;7: 1.
76. Xiao YH, Giske CG, Wei ZQ, et al. Epidemiology and characteristics of antimicrobial resistance in China. Drug Resist Update. 2011;14: 236–50.
77. Ovetchkine P, Rieder MJ; Canadian Paediatric Society, Drug Therapy and Hazardous Substances Committee. Azithromycin use in paediatrics: a practical overview. Paediatr Child Health. 2013;18: 311–6.
78. Xiao Y, Zhang J, Zheng B, et al. Changes in Chinese policies to promote the rational use of antibiotics. PLoS Med. 2013;10: e1001556.
79. Santa-Ana-Tellez Y, Mantel-Teeuwisse A, Dresner A, et al. Impact of over-the-counter restrictions on antibiotic consumption in Brazil and Mexico. PLoS One. 2013;8: e75550.
80. Chabicz M, Chabicz S, Marcinowicz L, et al. Outpatient use of systemic antibiotics in Poland: 2004-2008. Przegl Epidemiol. 2014;68: 435–41.
81. Fürst J, Čižman M, Mrak J, et al. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. Expert Rev Anti Infect Ther. 2015;13: 279–89.
82. Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006;50: 709–12.
83. Matsubara K, Morozumi M, Okada T, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in paediatric patients. J Infect Chemother. 2009;15: 380–3.
84. Kawai Y, Miyashita N, Kubo M, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Antimicrob Agents Chemother. 2013;57: 2252–8.
85. Bao F, Qu J-X, Liu Z-J, Cao B. The clinical characteristics, treatment and outcome of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Chin J Tuberc Respir Dis. 2013;36: 756–61.
86. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008;117: 393–405.
87. Cassell GH, Drnec J, Waites KB, Pate MS, Duffy LB, Watson HL, McIntosh JC. Efficacy of clarithromycin against Mycoplasma pneumoniae. J Antimicrob Chem. 1991;27(Suppl. A): 47–59.
88. Schönwald S, Skerk V, Petricevic I, Car V, Majerus-Misic L, Gunjaca M. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur J Clin Microbiol Infect Dis. 1991;10: 877–80.
89. Morozumi M, Iwata S, Hasegawa K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in paediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008;52: 348–50.
90. Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis. 2012;55: 1642–9.
91. Miyashita N, Akaike H, Teranishi H, et al. Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy. Antimicrob Agents Chemother. 2013;57: 5181–5.
92. Doxycycline Hyclate - FDA prescribing information, side effects and uses. Available at: http://www.drugs.com/pro/doxycycline-hyclate.html,2015/06.
93. Conchie JM, Munroe JD, Anderson DO. The incidence of staining of permanent teeth by the tetracyclines. Can Med Assoc J. 1970;103: 351–6.
94. Yamazaki T, Sasaki T, Takahata M. Activity of garenoxacin against macrolide-susceptible and – resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2007;51: 2278–9.
95. Waites KB, Crabb DM, Duffy LB. Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agent Chemother. 2008;52: 3776–8.
96. Miyashita N, Maruyama T, Kobayashi T, et al. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother. 2011;17: 114–18.
97. Hantz S, Garnier F, Peuchant O, et al. Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child. J Clin Microbiol. 2012;50: 3402–5.
98. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl. 2): S144–57.
99. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007;26(10): 879–91.
100. File TM, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. Today's Ther Trends. 2001;19: 251–70.
101. File TM, Schlemmer B, Garau J, et al.; 049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemo C. 2001;48: 67–74.
102. Hoeffken G, Talan D, Larsen LS, et al. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. Eur J Clin Microbiol Infect Dis. 2004;23: 772–5.
103. Bradley JS, Jackson MA; Committee on Infectious Diseases, American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics. 2011;128: e1034–45.